{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:25:32Z","timestamp":1773296732590,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jocn.2018.01.040","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T15:57:33Z","timestamp":1517500653000},"page":"154-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report"],"prefix":"10.1016","volume":"50","author":[{"given":"Davis G.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam U.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward H.","family":"Oldfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok R.","family":"Asthagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2018.01.040_b0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/jns.2006.105.2.248","article-title":"Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment","volume":"105","author":"Ammerman","year":"2006","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2018.01.040_b0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00280-013-2191-0","article-title":"Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma","volume":"72","author":"Bonate","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jocn.2018.01.040_b0015","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jama.300.11.1334","article-title":"Neurologic manifestations of von Hippel-Lindau disease","volume":"300","author":"Butman","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2018.01.040_b0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/OAJU.S5896","article-title":"Pazopanib and anti-VEGF therapy","volume":"2","author":"Drabkin","year":"2010","journal-title":"Open Access J Urol"},{"key":"10.1016\/j.jocn.2018.01.040_b0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9440(10)65541-1","article-title":"Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF\/HIF-2alpha","volume":"153","author":"Flamme","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jocn.2018.01.040_b0030","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1038\/onc.2014.407","article-title":"RSUME inhibits VHL and regulates its tumor suppressor function","volume":"34","author":"Gerez","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jocn.2018.01.040_b0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3171\/jns.2002.97.4.0977","article-title":"Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity","volume":"97","author":"Gijtenbeek","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2018.01.040_b0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2018.01.040_b0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jocn.2018.01.040_b0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-012-0214-0","article-title":"Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report","volume":"7","author":"Kim","year":"2012","journal-title":"Target Oncol"},{"key":"10.1016\/j.jocn.2018.01.040_b0055","first-page":"514","article-title":"Mutation and cancer: neuroblastoma and pheochromocytoma","volume":"24","author":"Knudson","year":"1972","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jocn.2018.01.040_b0060","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1517\/14656566.2015.1058359","article-title":"First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis","volume":"16","author":"Larkin","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jocn.2018.01.040_b0065","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","article-title":"Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease","volume":"120","author":"Lonser","year":"2014","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2018.01.040_b0070","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2018.01.040_b0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/cns.15.22","article-title":"Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review","volume":"4","author":"Migliorini","year":"2015","journal-title":"CNS Oncol"},{"key":"10.1016\/j.jocn.2018.01.040_b0080","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jnci\/djt240","article-title":"New insights into von Hippel-Lindau function highlighted by investigation of the trichloroethylene-induced p. P81S hotspot mutation","volume":"105","author":"Neckers","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jocn.2018.01.040_b0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MOU.0000000000000207","article-title":"First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES","volume":"25","author":"Schmidinger","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jocn.2018.01.040_b0090","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2018.01.040_b0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3171\/jns.2003.98.1.0082","article-title":"The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease","volume":"98","author":"Wanebo","year":"2003","journal-title":"J Neurosurg"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817313152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817313152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T02:28:43Z","timestamp":1530584923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586817313152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":19,"alternative-id":["S0967586817313152"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2018.01.040","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2018.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}